Luminex hit a number of "unexpected speed bumps" in the third quarter that caused the company to miss both its internal and Wall Street's projections, and to lower its 2013 revenue guidance.

While the Austin, Texas-based company posted 1 percent growth for the three months ended Sept. 30, largely due to a 17 percent jump in royalty revenues, Luminex saw both its assay and system sales decline in the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.